The effectiveness and value of tezepelumab for severe asthma

J Manag Care Spec Pharm. 2022 May;28(5):577-580. doi: 10.18553/jmcp.2022.28.5.577.

Abstract

DISCLOSURES: Drs Rind, Campbell, Pearson, Ms Herce-Hagiwara, Ms Fluetsch, and Ms Herron-Smith report grants from Arnold Ventures; Kaiser Foundation Health Plan, Inc; The Patrick and Catherine Donaghue Medical Research Foundation; Blue Cross Blue Shield of Massachusetts; and California Healthcare Foundation during the course of this study.

MeSH terms

  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Asthma* / drug therapy
  • Cost-Benefit Analysis
  • Humans
  • Massachusetts

Substances

  • Antibodies, Monoclonal, Humanized
  • tezepelumab